Rosen Law Firm Encourages uniQure Investors to Secure Counsel Before Deadline

Investors who purchased uniQure shares during the Class Period may be entitled to compensation.

Mar. 29, 2026 at 2:35am

Got story updates? Submit your updates here. ›

The Rosen Law Firm, a global investor rights law firm, is reminding purchasers of uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025 of the important April 13, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that uniQure misrepresented and failed to disclose information about the design of its Pivotal Study and the likelihood of delays in its Biologics License Application timeline.

Why it matters

This case highlights the importance of transparency and accurate disclosures by public companies, especially regarding the status of clinical trials and regulatory filings. Investors rely on this information to make informed decisions, and any misrepresentations can lead to significant losses.

The details

According to the lawsuit, uniQure allegedly misrepresented and failed to disclose that: (1) the design of its Pivotal Study for its leading drug candidate in Huntington's Disease was not fully approved by the FDA; (2) the company downplayed the likelihood of delays in its Biologics License Application timeline, despite the need to perform additional studies; and (3) as a result, the company's statements about its business, operations, and prospects lacked a reasonable basis.

  • The Class Period is from September 24, 2025 to October 31, 2025.
  • The lead plaintiff deadline is April 13, 2026.

The players

uniQure N.V.

A biopharmaceutical company focused on the development of gene therapies for rare genetic disorders.

The Rosen Law Firm, P.A.

A global investor rights law firm that represents investors throughout the world, concentrating its practice in securities class actions and shareholder derivative litigation.

Got photos? Submit your photos here. ›

What they’re saying

“To join the uniQure class action, go to https://rosenlegal.com/submit-form/?case_id=53025 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.”

— Phillip Kim, Esq.

“Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar.”

— Laurence Rosen, Founding Partner

What’s next

Investors have until April 13, 2026 to move the Court to serve as lead plaintiff in the uniQure securities class action lawsuit.

The takeaway

This case highlights the importance of transparency and accurate disclosures by public companies, especially regarding the status of clinical trials and regulatory filings. Investors rely on this information to make informed decisions, and any misrepresentations can lead to significant losses.